Neurocrine Biosciences (NBIX) EV to EBITDA (2011 - 2026)
Neurocrine Biosciences' EV to EBITDA was 14.04 in Q3 2026, down 36.8% from 22.21 a year earlier and down 29.3% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EV to EBITDA (2011 - 2026) Analysis & Trends
On a trailing twelve-month basis, Neurocrine Biosciences' EV to EBITDA was 10.76 through Sep 30, 2026, down 36.9% year-over-year; for FY2025, it came in at 19.59, down 6.3% from FY2024.
- In earlier years, EV to EBITDA was 20.90 in FY2024 (-52.3%), 43.84 in FY2023 (+10.7%), 39.61 in FY2022 (-30.3%) and 56.85 in FY2021 (+33.5%).
- The Q3 2026 figure marks the lowest quarterly EV to EBITDA since Q2 2012.
- Compared with a year earlier, EV to EBITDA has declined for four straight quarters, with an average decline of 16.3% over the last eight quarters.
- The best year-over-year quarter for EV to EBITDA over five years was Q3 2022 (growth of 108.7%); the worst was Q3 2024 (a decline of 61.0%).
- Per Business Quant data, NBIX's EV to EBITDA in the three quarters before Q3 2026 was 19.87 (Q2 2026), 14.58 (Q1 2026) and 19.59 (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Neurocrine Biosciences | 17.13 Bn | 13.21 Bn | 1.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 14.04 |
| Jun 30, 2026 | 19.87 |
| Mar 31, 2026 | 14.58 |
| Dec 31, 2025 | 19.59 |
| Sep 30, 2025 | 22.21 |
| Jun 30, 2025 | 21.91 |
| Mar 31, 2025 | 19.12 |
| Dec 31, 2024 | 20.90 |
| Sep 30, 2024 | 17.25 |
| Jun 30, 2024 | 22.90 |
| Mar 31, 2024 | 25.98 |
| Dec 31, 2023 | 43.84 |
| Sep 30, 2023 | 44.27 |
| Jun 30, 2023 | 48.42 |
| Mar 31, 2023 | 59.83 |
| Dec 31, 2022 | 39.61 |
| Sep 30, 2022 | 73.15 |
| Jun 30, 2022 | 98.42 |
| Mar 31, 2022 | 84.14 |
| Dec 31, 2021 | 56.85 |
API Access
Neurocrine Biosciences EV to EBITDA API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-ebitda", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();